[1]CurrentPatentAssignee:ASTRAZENECAPLC-WO2007/45844,2007,A1Locationinpatent:Page/Pagecolumn41
[2]CurrentPatentAssignee:ASTRAZENECAPLC-WO2007/45844,2007,A1Locationinpatent:Page/Pagecolumn42
Title: Eyre TA, et al. Predictive biomarkers for disease sensitivity in lymphoma - the holy grail for HDAC inhibitors? Oncotarget. 2018 Dec 18;9(99):37280-37281.
Title: Eyre TA, et al. A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer. Cancer. 2019 Jan 1;125(1):99-108.